At the ESMO congress held in Paris, France, and virtually from 9th -13th September, 2022, practice-changing data and high-quality education attracted more than 29,300 participants from over 150 countries. The meeting made this year’s tagline “understanding the disease to provide better care for cancer patients” more than just a slogan, thus, this report provides a comprehensive overview of on different solid tumor entities. New clinical insights in head and necks quamous cell carcinoma, hepatocellular carcinoma, gastric cancer and gastroesophageal junction adenocarcinoma, renal cell carcinoma, colorectal cancer as well as novel early clinical approaches, including CLDN6 CAR-T cell therapy, a GDF-15 neutralizing antibody, an MDM2 inhibitor, an antibody-drug conjugate, or even a new class of T-cell-redirecting bispecific fusionproteins, as well as an anti-TIGIT antibody to elicit a meaningful tumorresponse are summarized.
As an additional feature, you will find expert video interviews with Stacey A. Cohen on various conference highlights on our website. 

Download the report, or visit memo inOncology

Access anarticle directly (English):

Preface

New clinical insights in head and neck squamous cell carcinoma

Update on the treatment of advanced HCC

Towards treating all stages of gastric cancer and gastroesophageal junction adenocarcinoma

From neoadjuvant to second-line therapeutic options for RCC resected patients

Promising therapeutic strategies for colorectal cancer treatment

Novel early clinical approaches in solid tumors

DOWNLOAD (ENGLISH)

Slide kit (English)